A trademark for the drug lovastatin.
References in periodicals archive ?
xx Advicor, Altocor, Altoprev, Caduet, cholestyramine, cholestyramine light, Colestid, Crestor, fenofibrate, gemfibrozil, Lescol, Lescol XL, Lipitor, Locholest, Lofibra, Lopid, lovastatin, Mevacor, Niaspan, Pravachol, Pravigard PAC, Prevalite, Questran, Questran Light, Tricor, Welchol, Zetia, Zocor Depression 296.
TABLE: SIMILAR SOUNDING DRUG NAMES THAT COULD RESULT IN A MEDICATION ERROR Drug Name Confused With Abelcet Amphotericin B Accupril Aciphex Acetazolamide Acetohexamide Aciphex Aricept Aciphex Accupril Activase TNKase Actonel Actos Adderall Inderal Advicor Altocor Aggrastat Argatroban Adapted from Medication Safety Alert.
As part of this settlement, Andrx will pay Kos $6 million and has agreed to cease using the Altocor trademark for any of its products to avoid further confusion between Andrx's cholesterol product, Altocor, and Kos' highly differentiated cholesterol product, Advicor(R).
In response to an increasing need for affordable access to prescription medications, Andrx Corporation today announced the national launch of its innovative SAVE (Select Altocor for Value & Effectiveness) Program to help the growing number of uninsured and under-insured Americans afford needed cholesterol therapy.
Andrx Corporation (Nasdaq:ADRX) announced that, effective June 19, 2004, Andrx will begin marketing its cholesterol-lowering brand product Altocor (lovastatin extended-release tablets) under the name Altoprev(TM).
On September 12, Andrx (ADRX) announced that the FDA had granted final approval for us of Altocor for the primary prevention of coronary heart disease in patients without symptomatic cardiovascular disease who have average to moderately elevated total cholesterol and LDL-cholesterol, as well as, below average HDL-cholesterol.
The Company also announced today that, in order to avoid possible confusion in the marketplace, it is in discussions with the FDA to market its Altocor product under a new name.
Revenues for 2003 from brand products include a full year of sales of Altocor, which totaled $32.
This increase primarily resulted from net sales of Altocor of $10.
Altocor was also added to Medi-Cal, California's state Medicaid drug list.
One poster presents a cost-effectiveness model comparing Altocor to generic lovastatin and the other poster presents the preliminary data from a clinical trail comparing Altocor versus Atorvastatin (Lipitor(R)).